医药联合随访与院社优化沟通对药物不良事件急诊再入院的影响:URGEIM随机对照试验研究方案
BACKGROUND: Adverse drug events (ADE) represent one of the main causes of admission to emergency department (ED). Their detection, documentation, and reporting are essential to avoid readmission.…
要点
- 药师-医师双人识别急诊ADE患者,随机接受多学科过渡期照护联合用药数据传递干预或常规照护。
- 主要终点为6个月内同一ADE导致急诊再入院率,终点评估对分组设盲。
- 若干预成功,可考虑在其他医院推广临床药师参与急诊的模式。
核心结论
- 研究假设药师主导的多学科过渡期照护项目联合用药数据传递可减少ADE相关急诊再入院。
- 试验结果将影响临床药师在急诊科的角色定位,若干预成功可考虑跨医院推广。
研究设计与样本
- 随机分为实验组(多学科过渡期照护项目及住院与门诊照护者间用药数据传递)和对照组(常规照护),随访6个月。
- 终点评估对随机分组设盲,主要终点数据通过电话随访患者及其全科医生收集。
关键数值与推荐
- 主要终点为6个月内因同一原因至少一次急诊再入院患者的比例。
临床怎么用
- 若试验成功,药师参与急诊的多学科过渡期照护联合用药数据传递可作为减少ADE相关急诊再入院的干预模式。
局限性
- 开放标签设计,但终点评估对随机分组设盲。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adverse drug events (ADE) represent one of the main causes of admission to emergency department (ED). Their detection, documentation, and reporting are essential to avoid readmission. We hypothesize that a pharmacist-initiated multidisciplinary transition of care program combining ED pharmacist contribution and medications' data transfer between inpatient and outpatient caregivers will reduce emergency visits related to ADE METHOD/DESIGN: This is a prospective, open-label, randomized controlled trial. The primary aim of the study is 6-month ED readmission related to the same ADE. Three hundred forty-six adult patients with an ADE detected by a binomial pharmacist-physician will be recruited from the ED of an University Hospital and will be randomized in two groups: [1] experimental group (multidisciplinary transition of care program and medications' data transfer between inpatient and outpatient caregivers) and [2] control group (usual care). Patients will be followed up over a period of 6 months. Endpoints will be carried out blindly of the randomization arm. The primary endpoint is the rate of patients who had at least one readmission in the ED for the same reason at 6 months (data collected during a phone call with the patient and the general practitioner). Trials registered NCT03725046. DISCUSSION: The trial results will have implications for the role of the clinical pharmacist in an emergency department. If successful, the intervention could be considered for implementation across other hospitals. TRIAL REGISTRATION: ClinicalTrials.gov NCT03725046 . Registered on 30 October 2018.
引用
- Breuker C, Faucanié M, Laureau M, et al. Impact of a medico-pharmaceutical follow-up and an optimized communication between hospital and community on the readmission to the emergency department for an adverse drug event: URGEIM, study protocol for a randomized controlled trial. Trials. 2021. PMID: 34362410. doi:10.1186/s13063-021-05501-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。